Botanical Drug CMC Requirements Should Track OTC Monographs - AHPA
This article was originally published in The Tan Sheet
Executive Summary
Chemistry, manufacturing and controls (CMC) information should not be a prerequisite for botanical OTCs if it is not required for non-botanical OTC drugs, the American Herbal Products Association says.
You may also be interested in...
FDA Botanical Drug Products Final Guidance Stresses Batch Consistency
An FDA final guidance on botanical drug products includes new language recommending that firms demonstrate "batch-to-batch consistency" for botanical drug candidates through the clinical development process prior to submitting an NDA
Protocol Review, Clinical Trial Conduct Purview Of New NCCAM Office
NCCAM's Office of Clinical & Regulatory Affairs expects to use an FDA draft guidance on botanical drug products as a starting point for reviewing research protocols and overseeing clinical trials funded by the center, OCRA Director Jonathan Berman, MD/PhD, said Aug. 26
Botanical/Drug Interaction Studies Should Be Based On Safety Risk - CHPA
"Extensive" investigation of drug-drug interactions for botanical drug products is not necessary unless a safety risk is indicated by adverse event reports or other animal or clinical data, the Consumer Healthcare Products Association asserts.